Lupin gains on launching combination drugs for heart failure patients

Lupin gains on launching combination drugs for heart failure patients

Indian Market
by 5paisa Research Team Last Updated: 2023-01-19T09:30:50+05:30

Today, the stock opened at Rs 753.00 and has touched a high and low of Rs 769.70 and Rs 753.00, respectively.

On Wednesday, shares of Lupin closed at Rs 766.90, up by 13.85 points or 1.84% from its previous closing of Rs 753.05 on the BSE.

Lupin has launched combination drugs Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, “Heart failure is a difficult condition with severe unmet needs, necessitating the development of treatment agents to improve patient outcomes. As a leader in the cardiac therapy area, Lupin is committed to offering patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need while reducing the cost of therapy.” 

Lupin is an innovation-led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

The BSE group 'A' stock of face value of Rs 2 has a 52-week high and low of Rs 969.00 and Rs 583.05. Last one week high and low of the scrip stood at Rs 769.70 and Rs 745.15, respectively. The current market cap of the company is Rs 34,875.59 crore.

The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.

Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.

Open Free Demat Account

& get benefits worth 2100*

Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number